Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
However, these won’t be available at the nearest chemist store soon
First launches expected in H1 2022
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
It provides Covid-19 detection and Omicron surveillance in less than two hours
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
It is the first monoclonal antibody drug for use in any animal species
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
